2024 revenue fell 23.5% and net profit dropped 80.4% year-over-year, mainly due to asset impairments and industry price pressures. Innovative cardiovascular products and international expansion remain key growth drivers, with R&D investment at 19% of revenue.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.